55 completed, 13 recruiting, 11 unknown, 6 not yet recruiting. 94 Phase 2, 15 Phase 1, 10 Phase 3.
Follow Atrophy: new trials by email Literature Review of Atrophy trials Research Report on Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck Nutrition counseling, Fresubin Supportan - Head &Amp;Amp; Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Anna Arthur, PhD | 15 | 2027-06-01 | 2026-08-07 |
| Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia EN001, EN001 Placebo - Sarcopenia | Phase 1 / Phase 2 | Not yet recruiting | ENCell | 132 | 2027-03-01 | 2026-09-11 |
| HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide Calcium-HMB Plus Vitamin D3, Matching placebo - Type 2 Diabetes Mellitus (T2DM), Sarcopenia | Phase 2 | Not yet recruiting | Vanderbilt University Medical Center | 90 | 2026-12-01 | 2026-08-28 |
| GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD Tirzepatide - COPD, Obesity & Overweight | Phase 2 | Not yet recruiting | The Cleveland Clinic | 30 | 2026-08-28 | 2026-08-05 |
| Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. BIO101, Placebo, Semaglutide - Muscle Wasting, Obesity & Overweight | Phase 2 | Not yet recruiting | Biophytis | 164 | 2026-07-01 | 2026-02-13 |
| Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia TJ0113, Placebo - Sarcopenia | Phase 2 | Recruiting | Hangzhou PhecdaMed Co., Ltd. | 204 | 2026-06-12 | 2026-08-05 |
| CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy AAV9-Follistatin gene therapy, VEGF Plasmid - Age-related Muscle Decline | Phase 1 / Phase 2 | Recruiting | Unlimited Biotechnology LLC | 12 | 2026-06-01 | 2026-07-13 |
| A Study of PLH-2301 in Subjects With Sarcopenia PLH-2301, Placebo - Sarcopenia in Elderly | Phase 2 | Recruiting | Pluto Inc. | 168 | 2026-05-08 | 2026-05-12 |
| Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia CG-BM1- 5.0 × 10^7 cells, CG-BM1-1.0 × 10^8 cells - Sarcopenia | Phase 1 / Phase 2 | Recruiting | GuangZhou Cellgenes Biotechnology Co., Ltd. | 30 | 2026-04-30 | 2026-10-14 |
| TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status TCM Formula, HMB (beta-Hydroxy-beta-methylbutyrate) - Pre-Frailty, Sarcopenia | Phase 2 | Recruiting | Tri-Service General Hospital (TSGH) | 90 | 2026-04-02 | 2026-05-19 |
| Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults Tirzepatide - Obesity Prevention, Sarcopenia in Elderly | Phase 2 | Recruiting | The University of Texas Health Science Center at San Antonio | 20 | 2026-04-01 | 2026-04-15 |
| Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction Oxandrolone, Placebo - Anterior Cruciate Ligament (ACL) Reconstruction | Phase 2 | Recruiting | Science Valley Research Institute | 96 | 2025-11-28 | 2026-08-25 |
| A Study of AMC6156 in People With Sarcopenia AMC6156 0.1mg, AMC6156 0.3mg, AMC6156 1.0mg - Sarcopenia in Elderly, Sarcopenia | Phase 2 | Recruiting | Animuscure Inc. | 80 | 2025-07-01 | 2026-08-03 |
| A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) (S)-pindolol benzoate, Semaglutide, Placebo to (S)-pindolol benzoate - Obesity, Muscle Loss | Phase 2 | Recruiting | Actimed Therapeutics Ltd | 120 | 2025-06-23 | 2026-02-17 |
| Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures Isomyosamine 250mg, Placebo 250 mg - Sarcopenia in Elderly, Frailty | Phase 2 | Not yet recruiting | TNF Pharmaceuticals, Inc. | 60 | 2025-05-01 | 2025-04-24 |
| Personalized Pharmaconutrition Therapy for Myosteatosis, Sarcopenia, and Prognosis in Gastric Cancer Patients Pharmaconutrition - Myosteatosis, Sarcopenia | Phase 2 | Completed | Biruni University | 40 | 2024-10-16 | 2026-03-12 |
| Essential Amino Acid Supplementation for Femoral Fragility Fractures Essential Amino Acid Supplementation - Femoral Fracture, Fragility Fracture | Phase 2 | Recruiting | Michael C Willey | 60 | 2024-06-17 | 2026-10-07 |
| Whole Grain Job's Tear, Muscle Health, Blood Glucose and Lipid Level Taiwanese whole grain job's tear (red job's tear), White job's tear - Sarcopenia, Frailty | Phase 2 | Unknown | Taipei Veterans General Hospital, Taiwan | 80 | 2024-06-14 | 2024-07-16 |
| Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt Enobosarm, Semaglutide - Muscle Loss, Obesity | Phase 2 | Completed | Veru Inc. | 168 | 2024-04-29 | 2025-09-17 |
| Nutritional Therapy in Late-onset Pompe Disease Multi-ingredient supplement (PDT-MIS), Placebo (PLA) - Pompe Disease, Muscle Loss | Phase 2 | Unknown | McMaster University | 28 | 2024-04-01 | 2023-11-14 |
Showing 20 of 94. Sign in to see all of them.
Sarcopenia (47) · Muscular Atrophy (45) · Frailty (10) · Obesity (9) · Muscle Weakness (5) · Weight Loss (5) · Insulin Resistance (4) · Osteoporosis (4) · Asthenia (3) · Critical Illness (3) · Liver Cirrhosis (3) · Motor Activity (3) · Neoplasms (3) · Pulmonary Disease, Chronic Obstructive (3)
Pathological Conditions, Signs and Symptoms (94) · Pathological Conditions, Anatomical (93) · Nervous System Diseases (87) · Neurologic Manifestations (87) · Signs and Symptoms (87) · Neuromuscular Manifestations (85) · Muscular Atrophy (41) · Pathologic Processes (26) · Nutritional and Metabolic Diseases (24) · Metabolic Diseases (16) · Body Weight (13) · Musculoskeletal Diseases (12) · Nutrition Disorders (10) · Overnutrition (9)
beta-hydroxyisovaleric acid (5) · bimagrumab (5) · Resistance Training (3) · semaglutide (3) · Amino Acids, Essential (2) · Growth Hormone (2) · Leucine (2) · Standard of Care (2) · Testosterone (2) · Tirzepatide (2) · mecobalamin (2) · nicotinamide-beta-riboside (2) · ostarine (2) · AMG 745 (1) · Acetylcysteine (1)
Novartis Pharmaceuticals (5) · VA Office of Research and Development (3) · Biophytis (2) · Eisai Co., Ltd. (2) · Maastricht University Medical Center (2) · National Institute on Aging (NIA) (2) · TNF Pharmaceuticals, Inc. (2) · University of Washington (2) · AHS Cancer Control Alberta (1) · Actimed Therapeutics Ltd (1) · Amgen (1) · Animuscure Inc. (1) · Anna Arthur, PhD (1) · Assistance Publique - Hôpitaux de Paris (1) · Aventi Biotechnology Inc. (1)
United States (47) · France (8) · Spain (8) · Belgium (7) · Japan (7) · Canada (6) · Netherlands (6) · South Korea (6) · Taiwan (6) · United Kingdom (6) · Denmark (5) · Australia (4) · Switzerland (4) · China (3) · Czechia (3)
Jeremy Walston, MD (2) · Kazunori Saeki (2) · Luc JC van Loon, PhD (2) · Ahmed Reda, Lecturer (1) · Aino F Jonasson, MD (1) · Amr Zahran, Professor (1) · Amy Attaway, MD (1) · Anchun Hwang, Doctor (1) · Andres Duarte-Rojo, M.D. (1) · Anne R. Cappola, M.D.,Sc.M. (1) · Baback Roshanravan, MD (1) · Bess Dawson-Hughes, M.D. (1)
PMID 19106243, PMID 19321567, PMID 19446324, PMID 20739716, PMID 21389329, PMID 21543538, PMID 21631380, PMID 21753869, PMID 23499390, PMID 23732550, PMID 24012740, PMID 24326421, PMID 25923482, PMID 25973477, PMID 25982504, PMID 26733251, PMID 26829246, PMID 26950683, PMID 26980371, PMID 27999607, PMID 28508697, PMID 28842733, PMID 29211866, PMID 29556926, PMID 30095981, PMID 30280129, PMID 30636701, PMID 31343947, PMID 31397289, PMID 32452208, PMID 32792420, PMID 33074327, PMID 33246973, PMID 34029521, PMID 34579024, PMID 35170737, PMID 35511890, PMID 35565223, PMID 35854224, PMID 36098133, PMID 36209245, PMID 36905161, PMID 37159264, PMID 38049955, PMID 38330285, PMID 38525752, PMID 38877464, PMID 39513970, PMID 39847432, PMID 40449504
2015 (1), 2016 (1), 2018 (1), 2023 (1), K23DK099442 (1), P30AG021334 (1), P30AG028740 (1), R01AG018169 (1), R01AG046401 (1), R01AR060261 (1), R01CA254955 (1), R01DK101509 (1), R01HD068712 (1), UL1TR001998 (1)